The increased PAI-1 expression among severely ill COVID-19 subjects contributes to the hypercoagulability of the condition, as PAI-1 independently inhibits tissue plasminogen activator and contributes significantly to the development of thrombotic events [10]. The gene discussed is SERPINE1; the disease is COVID-19.